UVA Finds New Way to Treat Deadliest Brain Cancer

Scientists at the University of Virginia may have cracked a major code in fighting the world's deadliest brain cancer.

A team at UVA's Comprehensive Cancer Center has developed an experimental approach to treat glioblastoma, a devastating diagnosis that typically gives patients just months to live. Even with surgery, radiation, and chemotherapy, most patients survive only 12 to 18 months.

Dr. Roger Abounader, who leads the research team, explains why glioblastoma is so difficult to beat. The cancer involves numerous complex molecular changes, and most don't have drugs that can target them safely.

"If you combine several drugs if they existed, this would lead to an exponential increase in toxicity," Abounader said.

The breakthrough centers on microRNAs, small molecules that occur naturally in the human body. These tiny powerhouses can shut down multiple malfunctioning genes at once, the very genes responsible for glioblastoma's formation and growth.

The real innovation lies in delivery. The researchers combined brain-penetrating nanoparticles with focused ultrasound waves and microbubbles to smuggle the microRNAs through the brain's natural protective barrier, which normally blocks treatments for tumors and neurodegenerative diseases.

This three-pronged delivery system solves one of medicine's toughest challenges: getting healing compounds past the brain's defenses without causing harm.

Why This Inspires

This approach represents more than hope for glioblastoma patients. Because microRNAs are naturally occurring in humans and can target multiple genes simultaneously, they avoid the devastating toxicity that comes with combining traditional cancer drugs.

The method could extend beyond brain cancer. Abounader believes this delivery system could work for other brain diseases and cancers throughout the body, multiplying its potential impact.

UVA is one of only 57 cancer centers nationwide to earn the elite "comprehensive" designation from the National Cancer Institute. The research aligns perfectly with the mission of UVA's new Paul and Diane Manning Institute of Biotechnology, set to open in late 2027 specifically to accelerate development of treatments for complex diseases like glioblastoma.

More research is needed before human trials can begin, but the results show genuine promise.

"We and many others are intensively working to lighten the burden of cancer, and hopefully also completely cure it," Abounader said. "But this requires a continued investment in cancer and medical research."

For the 13,000 American families touched by glioblastoma each year, that investment is bringing new reasons for hope.